Bicycle Therapeutics (BCYC) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Larimar Therapeutics (LRMR) has outperformed Bicycle Therapeutics (BCYC) over the past year, losing 41.7% versus a loss of 53.4%. Over five years, LRMR leads with a -77.3% price change compared with -93.7% for BCYC. Larimar Therapeutics is the larger company by market cap ($280.5 million vs $266.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCYC | LRMR |
|---|---|---|
| Share price | $3.81 | $2.70 |
| Market cap | $266.67M | $280.48M |
| 1-day change | +2.14% | -1.82% |
| YTD return | -47.32% | -27.82% |
| 1-year return | -53.37% | -41.74% |
| 5-year return | -93.71% | -77.31% |
| EPS (TTM) | $-2.73 | $-1.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.16 | $6.42 |
| 52-week low | $3.33 | $2.61 |
| Distance from 52-week high | -58.40% | -57.94% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +149.34% | +433.33% |
| Average volume | 391.03K | 1.31M |
| Shares outstanding | 50.55M | 103.88M |
| Employees | 288 | 71 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LRMR has outperformed BCYC by 11.6 percentage points over the past year.
About Bicycle Therapeutics
BCYC stock →Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.
Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
BCYC vs LRMR FAQ
Which is bigger, Bicycle Therapeutics or Larimar Therapeutics?
Larimar Therapeutics (LRMR) is larger, with a market capitalization of $280.48M compared with $266.67M for Bicycle Therapeutics (BCYC).
Which stock has performed better over the past year, BCYC or LRMR?
LRMR returned -41.74% over the past 12 months, compared with -53.37% for BCYC (price return, excluding dividends). Past performance does not predict future results.
Are Bicycle Therapeutics and Larimar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.